Intech Biopharm Profit Margin

Intech Biopharm (6461.TWO) currently reports a profit margin of -992.81% as of June 2026. That compares with -279.67% in the prior-year period — down 255.0% year over year. That is below the Healthcare sector average of 10.58%. Use the charts on this page to explore Intech Biopharm's profit margin history and peer comparisons.

Intech Biopharm's profit margin decreased from -279.67% to -992.81% — a 255.0% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Intech Biopharm's profit margin of -992.81% is lower than the Healthcare sector average of 10.58%. That is roughly 9483.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Intech Biopharm's current -992.81% should be judged against Healthcare norms (sector average: 10.58%) and against 6461.TWO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -992.81%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 10.58%. From there, open related valuation or income-statement pages for Intech Biopharm, and consider following 6461.TWO for alerts when major investors trade the stock.